8-K filing — Ocugen, Inc. (OCGN)
Filed: 2026-10-15 AccNo: 0001104659-26-115970 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ocugen shares are trading lower. The company announced a licensing agreement with Roots Pharmaceutical for exclusive MENA rights to OCU400, its gene therapy for Retinitis Pigmentosa.
Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region
Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access to a potential
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.